Instgra
Instgra contains Dolutegravir (50mg), which is an integrase strand transfer inhibitor (INSTI). It blocks the replication of HIV by preventing the viral DNA from integrating into the genetic material of human immune cells, thereby reducing the viral load and helping to increase CD4 cell counts.
Dosage by Body Weight
The standard adult dose is 50 mg orally once daily, taken with or without food. In cases of documented integrase inhibitor resistance or when co-administered with certain metabolic inducers (like efavirenz, rifampin, or phenytoin), the dose may be increased to 50 mg twice daily. Pediatric dosage is determined by body weight and formulation availability.
- Body Weight
- Below 5 kg
- Dose
- Not routine
- Frequency
- Use only if prescribed
- Tracking Notes
- Safety and efficacy have not been established for infants weighing less than 3 kg.
- Body Weight
- 5-7 kg
- Dose
- 10 mg once daily
- Frequency
- Once daily
- Tracking Notes
- Administered using pediatric dispersible tablets.
- Body Weight
- 8-10 kg
- Dose
- 15 mg once daily
- Frequency
- Once daily
- Tracking Notes
- Administered using pediatric dispersible tablets.
- Body Weight
- 11-15 kg
- Dose
- 20 mg (dispersible) or 25 mg (film-coated) once daily
- Frequency
- Once daily
- Tracking Notes
- Dose and formulation should be chosen based on the patient's ability to swallow tablets.
- Body Weight
- 16-20 kg
- Dose
- 25 mg once daily
- Frequency
- Once daily
- Tracking Notes
- Using pediatric film-coated or dispersible tablets.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not routine | Use only if prescribed | Safety and efficacy have not been established for infants weighing less than 3 kg. |
| 5-7 kg | 10 mg once daily | Once daily | Administered using pediatric dispersible tablets. |
| 8-10 kg | 15 mg once daily | Once daily | Administered using pediatric dispersible tablets. |
| 11-15 kg | 20 mg (dispersible) or 25 mg (film-coated) once daily | Once daily | Dose and formulation should be chosen based on the patient's ability to swallow tablets. |
| 16-20 kg | 25 mg once daily | Once daily | Using pediatric film-coated or dispersible tablets. |
Formulation
Purpose
Used in combination with other antiretroviral agents for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and pediatric patients.
Generic Name
DolutegravirScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.